<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40300639</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Natural History of Anal Strictures in Pediatric-Onset Crohn's Disease: Long-term Follow-up of a Population-Based Study.</ArticleTitle><Pagination><StartPage>984</StartPage><EndPage>991</EndPage><MedlinePgn>984-991</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003788</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk and clinical course of anal stricture observed in Crohn's disease remains poorly known, particularly in pediatric-onset Crohn's disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the long-term clinical course of anal stricture in pediatric-onset Crohn's disease using data from a population-based cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective observational study from a prospective population-based registry.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Population-based study in Northern France.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with a diagnosis of Crohn's disease before the age of 17 years between 1988 and 2011 within the population-based registry EPIMAD were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome was the cumulative risk of anal stricture. Secondary outcomes included include risk of anal cancer, surgery, stoma, and risk factors associated with anal stricture.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1007 patients were included (median age at diagnosis 14.5 years [interquartile range, 12.0-16.1]; median duration of follow-up 8.8 years [interquartile range, 4.6-14.2]). Among them, 1 patient (0.1%) had an anal stricture at diagnosis and 26 (2.6%) had an anal stricture during follow-up. From diagnosis, the 5- and 10-year cumulative incidence of anal stricture at was 0.6% (95% CI, 0.1-1.1) and 1.4% (95% CI, 0.5-2.3), respectively. Twenty-five patients (n = 25/27; 93%) had at least 1 episode of anal ulceration or fistulizing perineal Crohn's disease. In multivariable analysis, extraintestinal manifestations (HR 2.2; 95% CI, 1.0-4.8; p = 0.0270), colonic location (colonic vs ileocolonic HR 1.2; 95% CI, 0.6-2.7; p = 0.0064) and a history of fistulizing perineal Crohn's disease (HR 9.9; 95% CI, 4.3-22.8; p &lt; 0.0001) were significantly associated with anal stricture. After a median follow-up of 6.2 years (2.4-10.6), 11 patients (41%) required at least 1 anal dilation, and healing was observed in 1 patient. One patient (3.7%) had an anal cancer 7 years after stricture diagnosis and 9 patients (33%) needed a stoma. Anal stricture was significantly associated with the need for stoma (HR 5.8; 95% CI, 2.3-14.3; p = 0.0002).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The retrospective design makes the study prone to selection bias and residual confounding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within a population-based cohort of pediatric-onset Crohn's diease, the 10-year cumulative incidence of anal stricture was 1.4%, with associations identified with colonic disease location and fistulizing perianal involvement. The presence of an anal stricture was linked to a 5-fold increase in the likelihood of stoma formation. See Video Abstract .</AbstractText><AbstractText Label="HISTORIA NATURAL DE LAS ESTENOSIS ANALES EN LA ENFERMEDAD DE CROHN DE INICIO PEDITRICO SEGUIMIENTO A LARGO PLAZO DE UN ESTUDIO POBLACIONAL" NlmCategory="UNASSIGNED">ANTECEDENTES:El riesgo y la evoluci&#xf3;n cl&#xed;nica de la estenosis anal observada en la enfermedad de Crohn siguen siendo poco conocidos, especialmente en la enfermedad de Crohn de inicio pedi&#xe1;trico.OBJETIVO:Investigar la evoluci&#xf3;n cl&#xed;nica a largo plazo de la estenosis anal en la EC de inicio pedi&#xe1;trico utilizando datos de una cohorte poblacional.DISE&#xd1;O:Estudio observacional retrospectivo a partir de un estudio poblacional prospectivo.ENTORNO CLINICO:Estudio poblacional en el norte de Francia.PACIENTES:Todos los pacientes con diagn&#xf3;stico de enfermedad de Crohn antes de los 17 a&#xf1;os, entre 1988 y 2011, incluidos en el registro poblacional EPIMAD.PRINCIPALES MEDIDAS DE RESULTADOS:La variable principal fue el riesgo acumulado de estenosis anal. Las variables secundarias incluyeron el riesgo de c&#xe1;ncer anal, cirug&#xed;a, estoma y factores de riesgo asociados con la estenosis anal.RESULTADOS:Se incluyeron 1007 pacientes (mediana de edad al diagn&#xf3;stico: 14,5 a&#xf1;os; RIQ: 12,0-16,1), con una mediana de seguimiento de 8,8 a&#xf1;os (RIQ: 4,6-14,2). Un paciente (0,1%) present&#xf3; estenosis anal al diagn&#xf3;stico y 26 (2,6%) durante el seguimiento. Desde el diagn&#xf3;stico, la incidencia acumulada de estenosis anal a los 5 y 10 a&#xf1;os fue del 0,6% (IC del 95%: 0,1-1,1) y del 1,4% (IC del 95%: 0,5-2,3), respectivamente. Veinticinco pacientes (n = 25/27, 93%) presentaron al menos un episodio de ulceraci&#xf3;n anal o enfermedad de Crohn perineal fistulizante. En el an&#xe1;lisis multivariable, las manifestaciones extraintestinales (HR 2,2, IC del 95 %, 1,0-4,8, p = 0,0270), la localizaci&#xf3;n col&#xf3;nica (L2 vs. L3 HR 1,2, IC del 95 %, 0,6-2,7, p = 0,0064) y el antecedente de enfermedad de Crohn perineal fistulizante (HR 9,9, IC del 95 %, 4,3-22,8, p &lt; 0,0001) se asociaron significativamente con la estenosis anal. Tras una mediana de seguimiento de 6,2 a&#xf1;os (2,4-10,6), 11 (41 %) pacientes requirieron al menos una dilataci&#xf3;n anal, y se observ&#xf3; curaci&#xf3;n en un paciente. Un paciente (3,7 %) present&#xf3; c&#xe1;ncer anal 7 a&#xf1;os despu&#xe9;s del diagn&#xf3;stico de la estenosis, y 9 (33 %) pacientes necesitaron un estoma. La estenosis anal se asoci&#xf3; significativamente con la necesidad de estoma (HR 5,8; IC del 95 %: 2,3-14,3; p = 0,0002).LIMITACIONES:El dise&#xf1;o retrospectivo del estudio lo hace propenso a sesgos de selecci&#xf3;n y factores de confusi&#xf3;n residuales.CONCLUSI&#xd3;N:En una cohorte poblacional de pacientes con enfermedad de Crohn de inicio pedi&#xe1;trico, la incidencia acumulada de estenosis anal a 10 a&#xf1;os fue del 1,4 %, con asociaciones identificadas con la localizaci&#xf3;n de la enfermedad col&#xf3;nica y la afectaci&#xf3;n perianal fistulizante. La presencia de estenosis anal est&#xe1; ligada a quintuplicar la probabilidad de formaci&#xf3;n de estoma. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mortreux</LastName><ForeName>Perrine</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroyer</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ley</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont-Lucas</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Le Havre Hospital, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillon</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wils</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coevoet</LastName><ForeName>Hugues B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, H&#xf4;pital Priv&#xe9; Les Bonnettes, Arras, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paupard</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dunkerque Hospital, Dunkerque, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gower-Rousseau</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Reims University Hospital, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siproudhis</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turck</LastName><ForeName>Dominique D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savoye</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Universit&#xe9; de Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis," CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarter</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Economic Health, Lille University Hospital, EPIMAD Registry, Regional House of Clinical Research, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE (Institute for Translational Research in Inflammation), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumery</LastName><ForeName>Mathurin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2337-2902</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EPIMAD Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C536215">Pediatric Crohn's disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001004" MajorTopicYN="Y">Anus Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anal stricture</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Perianal Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Population-based</Keyword><Keyword MajorTopicYN="N">Stoma</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Al Hameedi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Khatib</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Turk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agoute</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andre</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonietti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aouakli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armand</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armengol-Debeir</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aroichane</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aubet</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auxenfants</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avram</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayafi-Ramelot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azzouzi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bankovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardoux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baron</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baudet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayart</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bazin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bebahani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becqwort</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellati</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benet</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benali</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benguigui</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben Soussan</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bental</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkelmans</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernet</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernou-Dron</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertot</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertiaux-Vanda&#xeb;le</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billoud</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biron</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bismuth</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bleuet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondin</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bobula</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bondjemah</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boniface</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonkovski</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonni&#xe8;re</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonvarlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boruchowicz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bostvironnois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boualit</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouazza</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudaillez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeaux</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourguet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutaleb</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouthors</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branche</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bray</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breban</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridenne</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brihier</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bril</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brung-Lefebvre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulois</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgiere</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canva-Delcambre</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capron</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carette</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carpentier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartier</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassar</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassagnou</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castex</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catala</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cattan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catteau</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caujolle</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cayron</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandelier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chantre</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charneau</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavance-Thelu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheny</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chirita</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choteau</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claerbout</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clergue</LastName><ForeName>P Y</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coevoet</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collet</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colombel</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coopman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cordiez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvisart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortot</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couttenier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crinquette</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crombe</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dadamessi</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daoudi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dapvril</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davion</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dautreme</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Debas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decoster</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degrave</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dehont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delatre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delcenserie</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delesalle</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delette</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgrange</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delhoustal</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmotte</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demmane</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deregnaucourt</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Descombes</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desechalliers</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desmet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desreumaux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desseaux</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desurmont</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devienne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devouge</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devred</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devroux</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewailly</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dharancy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fiore</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djedir</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doleh</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dreher-Duwat</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duburque</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducatillon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duclay</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrocq</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrotte</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufilho</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duhamel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dujardin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumant-Forest</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupont</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duranton</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duriez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duveau</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Achkar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Farisi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elie-Legrand</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elkhaki</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eoche</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Essmaeel</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evrard</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatome</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filoche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finet</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flahaut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flamme</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foissey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein-Comes</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foutrein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fremond</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frere</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumery</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallais</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamblin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganga</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geslin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gheyssens</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghossini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghrib</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillet</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godard</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godchaux</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goegebeur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goria</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottrand</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gower</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandmaison</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groux</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guedon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerbeau</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gueroult-Dero</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillard</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillem</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillemot</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimber</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddouche</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hautefeuille</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckestweiller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hecquet</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedde</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellal</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henneresse</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heraud</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herve</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hochain</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssin-Bailly</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houcke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huguenin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iobagiu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Istanboli</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivanovic</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwanicki-Caron</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicki</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joly</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvenet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katherin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerleveo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachfe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiriakos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohut</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornhauser</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koutsomanis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laberenne</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacotte</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laffineur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagarde</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalanne</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalieu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannoy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapchin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laprand</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laude</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leblanc</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecieux</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecleire</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Couteulx</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ledent</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefiliatre</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Goffic</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legrand</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Grix</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lelong</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leluyer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenaerts</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepeut</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepileur</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leplat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepoutre-Dujardin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroy</LastName><ForeName>M Y</ForeName><Initials>MY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Roy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescanne-Darchis</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lescut</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leurent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lhermie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libier</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lion</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisambert</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loge</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loire</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loreau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louf</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louvet</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubret</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luciani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucidarme</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lugand</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macaigne</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maetz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maillard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mancheron</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manolache</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks-Brunel</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzloff</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathurin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauillon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maunoury</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maupas</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medam Djomo</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mechior</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melki</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesnard</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metayer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Methari</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meurisse</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaud</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirmaran</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modaine</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monthe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mortier</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moulin</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouterde</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozziconaci</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudry</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nachury</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngo</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>N'Guyen Khac</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Notteghem</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ollevier</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostyn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouraghi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oussadou</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouvry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paillot</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Painchart</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panien-Claudot</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paoletti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papazian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parent</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paupard</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauwels</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Penninck</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petit</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piat</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piotte</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plane</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plouvier</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pommelet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pop</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pordes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pouchain</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prades</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prevost</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quartier</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quesnel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Queuniet</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinton</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabache</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raclot</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratajczyk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rault</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razemon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reix</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renaut-Vantroys</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revillion</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riachi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riault</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saber</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savoye</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlossberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sefrioui</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segrestin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seguy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seminur</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seryer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sevenet</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekh</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvie</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spyckerelle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbodec</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavernier</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tchandeu</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Techy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thelu</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thevenin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiebault</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorel</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thuillier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tielman</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tode</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toisin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonnel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchais</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toumelin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touze</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tranvouez</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triplet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triki</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turck</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhlen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaillant</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valmage</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandaele-Bertiaux</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandamme</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderbecq</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vander Eecken</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandermolen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandevenne</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandeville</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandewalle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaneslander</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhoove</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanrenterghem</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanveuren</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varlet</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasies</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verbiese</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verlynde</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vernier-Massouille</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermelle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verne</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vezilier-Cocq</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigneron</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincendet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viot</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voiment</LastName><ForeName>Y M</ForeName><Initials>YM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wacrenier</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waeghemaecker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallez</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wantiez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wartel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willocquet</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wizla</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolschies</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaharia</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaoui</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zalar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaouri</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zellweger</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziade</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>29</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40300639</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003788</ArticleId><ArticleId IdType="pii">00003453-202508000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn&#x2019;s disease. Inflamm Bowel Dis. 2002;8:244&#x2013;250.</Citation></Reference><Reference><Citation>Freeman HJ. Natural history and clinical behavior of Crohn&#x2019;s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216&#x2013;219.</Citation></Reference><Reference><Citation>Peyrin-Biroulet L, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Perianal Crohn&#x2019;s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012;18:43&#x2013;48.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-year follow-up study of the natural history of perianal Crohn&#x2019;s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25:1227&#x2013;1236.</Citation></Reference><Reference><Citation>Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2009;15:383&#x2013;387.</Citation></Reference><Reference><Citation>Adler J, Dong S, Eder SJ, Dombkowski KJ; ImproveCareNow Pediatric IBD Learning Health System. Perianal Crohn disease in a large multicenter pediatric collaborative. J Pediatr Gastroenterol Nutr. 2017;64:e117&#x2013;e124.</Citation></Reference><Reference><Citation>Brochard C, Siproudhis L, Wallenhorst T, et al. Anorectal stricture in 102 patients with Crohn&#x2019;s disease: natural history in the era of biologics. Aliment Pharmacol Ther. 2014;40:796&#x2013;803.</Citation></Reference><Reference><Citation>Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn&#x2019;s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16:1431&#x2013;1442.</Citation></Reference><Reference><Citation>Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn&#x2019;s disease. Br J Surg. 1988;75:653&#x2013;655.</Citation></Reference><Reference><Citation>Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994;35:1433&#x2013;1438.</Citation></Reference><Reference><Citation>Ley D, Leroyer A, Dupont C, et al.; Epimad Group. New therapeutic strategies have changed the natural history of pediatric Crohn&#x2019;s disease: a two-decade population-based study. Clin Gastroenterol Hepatol. 2022;20:2588&#x2013;2597.e1.</Citation></Reference><Reference><Citation>Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314&#x2013;1321.</Citation></Reference><Reference><Citation>Fernandes MA, Verstraete SG, Garnett EA, Heyman MB. Addition of histology to the paris classification of pediatric Crohn disease alters classification of disease location. J Pediatr Gastroenterol Nutr. 2016;62:242&#x2013;245.</Citation></Reference><Reference><Citation>Mortreux P, Leroyer A, Ley D, et al. Natural history of anal stricture in pediatric-onset Crohn&#x2019;s disease: a two-decades population-based study. J Crohns Colitis. 2023;17:i315&#x2013;i316.</Citation></Reference><Reference><Citation>Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn&#x2019;s disease. A long-term perspective. Dis Colon Rectum. 1985;28:709&#x2013;711.</Citation></Reference><Reference><Citation>Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn&#x2019;s disease. Int J Colorectal Dis. 1986;1:104&#x2013;107.</Citation></Reference><Reference><Citation>Brochard C, Rabilloud ML, Hamonic S, et al.; Groupe ABERMAD. Natural history of perianal Crohn&#x2019;s disease: long-term follow-up of a population-based cohort. Clin Gastroenterol Hepatol. 2020;20:e102&#x2013;e110.</Citation></Reference><Reference><Citation>Fumery M, Pariente B, Sarter H, et al.; Epimad Group. Long-term outcome of pediatric-onset Crohn&#x2019;s disease: a population-based cohort study. Dig Liver Dis. 2019;51:496&#x2013;502.</Citation></Reference><Reference><Citation>Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2015;42:783&#x2013;792.</Citation></Reference><Reference><Citation>Burke JP. Role of fecal diversion in complex Crohn&#x2019;s disease. Clin Colon Rectal Surg. 2019;32:273&#x2013;279.</Citation></Reference><Reference><Citation>Hughes LE. Clinical classification of perianal Crohn&#x2019;s disease. Dis Colon Rectum. 1992;35:928&#x2013;932.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39476401</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1665-1731</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>Supl 3</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Archivos de cardiologia de Mexico</Title><ISOAbbreviation>Arch Cardiol Mex</ISOAbbreviation></Journal><ArticleTitle>Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>33</EndPage><MedlinePgn>1-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/ACM.M24000097</ELocationID><Abstract><AbstractText>La amiloidosis es una enfermedad heterog&#xe9;nea, de origen hereditario o adquirido, que se caracteriza por el dep&#xf3;sito anormal de prote&#xed;nas fibrilares en diversos tejidos. Esta enfermedad puede manifestarse de manera localizada o sist&#xe9;mica, lo que genera una amplia variabilidad en su presentaci&#xf3;n cl&#xed;nica y, frecuentemente, retrasa el diagn&#xf3;stico. Por ello, es fundamental la identificaci&#xf3;n temprana de los signos y s&#xed;ntomas para mejorar el pron&#xf3;stico. El primer posicionamiento mexicano sobre la amiloidosis card&#xed;aca tiene como objetivo resumir las principales caracter&#xed;sticas de la enfermedad y sus subtipos, identificando datos de alarma que incrementen la sospecha de su presencia. Adem&#xe1;s, busca ofrecer un algoritmo diagn&#xf3;stico que integre los estudios de imagen y de laboratorio disponibles en nuestro pa&#xed;s, con el fin de simplificar la toma de decisiones y llegar a un diagn&#xf3;stico de manera r&#xe1;pida, pr&#xe1;ctica y actualizada, basado en recomendaciones sustentadas en evidencia cient&#xed;fica. Una vez confirmado el diagn&#xf3;stico, se abordan los distintos retos terap&#xe9;uticos, tanto farmacol&#xf3;gicos como no farmacol&#xf3;gicos, ya que los pacientes no responden al tratamiento convencional de insuficiencia card&#xed;aca. Por ello, el tratamiento debe ser individualizado para cada paciente, teniendo en cuenta la presencia de otras comorbilidades. Finalmente, se presentan los principales factores pron&#xf3;sticos que guiar&#xe1;n un tratamiento adecuado, incluyendo los resultados del asesoramiento gen&#xe9;tico.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berrios-B&#xe1;rcenas</LastName><ForeName>Enrique A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cigarroa-L&#xf3;pez</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Mexicana de Insuficiencia Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Nacional de Cardi&#xf3;logos de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossio-Aranda</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Sociedad Mexicana de Cardiolog&#xed;a, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;squez-Ortiz</LastName><ForeName>Zuilma Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sociedad Nacional de Ecocardiograf&#xed;a de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro M&#xe9;dico ABC Santa Fe, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-D&#xed;ez</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sociedad Mexicana de Electrofisiolog&#xed;a y Estimulaci&#xf3;n Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeza-Herrera</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Regional de Alta Especialidad de la Pen&#xed;nsula de Yucat&#xe1;n, Yucat&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordero-Cabra</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Puerta de Hierro Norte, Jalisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Portano</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexanderson-Rosas</LastName><ForeName>Erick</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvajal-Ju&#xe1;rez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-Sangabriel</LastName><ForeName>Amada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jord&#xe1;n-R&#xed;os</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivey-Miranda</LastName><ForeName>Juan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escalante-Seyffert</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimaldo</LastName><ForeName>Flavio A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Reyes</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La&#xed;nez-Zelaya</LastName><ForeName>Jos&#xe9; S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Hospital Regional de Alta Especialidad Centenario de la Revoluci&#xf3;n Mexicana, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Morelos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara-Vargas</LastName><ForeName>Jorge A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meave-Gonz&#xe1;lez</LastName><ForeName>Aloha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibarra-Ibarra</LastName><ForeName>Blanca R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koretzky</LastName><ForeName>Solange G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Infantil de M&#xe9;xico Federico G&#xf3;mez, Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maga&#xf1;a-Serrano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Mexicana de Insuficiencia Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Nacional de Cardi&#xf3;logos de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>Posicionamiento mexicano para el diagn&#xf3;stico y tratamiento de amiloidosis cardiaca.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Arch Cardiol Mex</MedlineTA><NlmUniqueID>101126728</NlmUniqueID><ISSNLinking>1665-1731</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Amyloidosis is a heterogeneous, hereditary or acquired disease characterized by the abnormal deposition of fibrillar proteins in various tissues. The disease can be either localized or systemic, leading to significant variability in its clinical presentation and often causing diagnostic delays. For this reason, early identification of signs and symptoms is essential to improve prognosis. The first Mexican position paper on cardiac amyloidosis aims to summarize the main features of the disease and its subtypes, identifying warning signs that increase clinical suspicion. Additionally, it provides a diagnostic algorithm incorporating the imaging and laboratory studies available in our country, to streamline decision-making and facilitate a fast, practical, and up-to-date diagnosis based on evidence-based recommendations. Once the diagnosis is confirmed, the various therapeutic challenges of this disease, both pharmacological and non-pharmacological, are discussed, as patients do not respond to conventional heart failure treatments. Therefore, treatment must be individualized for each patient, considering the presence of other comorbidities. Finally, the key prognostic factors are outlined to guide appropriate treatment, including results from genetic counseling.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amiloidosis</Keyword><Keyword MajorTopicYN="N">Amiloidosis card&#xed;aca</Keyword><Keyword MajorTopicYN="N">Amiloidosis de inmunoglobulinas de cadenas ligeras</Keyword><Keyword MajorTopicYN="N">Amyloidosis</Keyword><Keyword MajorTopicYN="N">Cardiac amyloidosis</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Diagn&#xf3;stico</Keyword><Keyword MajorTopicYN="N">Prognosis. Treatment</Keyword><Keyword MajorTopicYN="N">Pron&#xf3;stico. Tratamiento</Keyword><Keyword MajorTopicYN="N">Transthyretin</Keyword><Keyword MajorTopicYN="N">Transtiretina</Keyword><Keyword MajorTopicYN="N">inmunoglobulin light-chain amyloidosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39476401</ArticleId><ArticleId IdType="pmc">PMC12169347</ArticleId><ArticleId IdType="doi">10.24875/ACM.M24000097</ArticleId><ArticleId IdType="pii">j94/Supl 3/1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392416</ArticleId><ArticleId IdType="pubmed">28373528</ArticleId></ArticleIdList></Reference><Reference><Citation>Correction to:Cardiac amyloidosis:Evolving diagnosis and management:A scientific statement from the American Heart Association. Circulation. 2021;144(1):e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34228483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311231</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi OK, Ruberg FL. Cardiac amyloidosis:An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28((1)):10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741539</ArticleId><ArticleId IdType="pubmed">28739313</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379((11)):1007&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6401262</ArticleId><ArticleId IdType="pubmed">30713046</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904524</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond) 2018;18((Suppl 2)):s30&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334035</ArticleId><ArticleId IdType="pubmed">29700090</ArticleId></ArticleIdList></Reference><Reference><Citation>Montserrat Moliner A, Waligora J. The European Union policy in the field of rare diseases. Adv Exp Med Biol. 2017;1031:561&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">29214592</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10084346</ArticleId><ArticleId IdType="pubmed">35509173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med. 2020;382((16)):1564&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MW, Barroso F, Gonz&#xe1;lez-Duarte A, Mundayat R, Ong ML. The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid. 2017;24:107&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28434322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Duarte A, C&#xe1;rdenas-Soto K, Ba&#xf1;uelos CE, Fueyo O, Dominguez C, Torres B, et al. Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases. Orphanet J Rare Dis. 2018;13(1):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029070</ArticleId><ArticleId IdType="pubmed">29970125</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad S, Goldberg YH, Bhopalwala H, Dewaswala N, Miceli NS, Birks EJ, et al. High prevalence of cardiac amyloidosis in clinically significant aortic stenosis:a meta-analysis. Cardiol Res. 2022;13(6):357&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9822671</ArticleId><ArticleId IdType="pubmed">36660066</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdi M, Mostafa MR, Abusnina W, Al-abdouh A, Doss R, Mohamed S, et al. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12(3):102&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301026</ArticleId><ArticleId IdType="pubmed">35873185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nils FK, Ana F, Mahmoud G, Mark H, Rozenbaum H. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy:a systematic review and meta-analysis. Cardiol Ther. 2021;10(1):41&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126539</ArticleId><ArticleId IdType="pubmed">33315233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021;3(4):537&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543133</ArticleId><ArticleId IdType="pubmed">34729526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis:clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647259</ArticleId><ArticleId IdType="pubmed">23608605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23479568</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32340017</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">30274625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17554117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattianayagam PT, Hawkins PN, Gillmore JD. Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2009;6(10):608&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">19724253</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis:current approaches to diagnosis and management. Hemasphere. 2020;4(4):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430233</ArticleId><ArticleId IdType="pubmed">32885146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, et al. Immunoglobulin light-chain amyloidosis:clinical presentations and diagnostic approach. J Adv Pract Oncol. 2019;10(5):470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779572</ArticleId><ArticleId IdType="pubmed">33457060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird J. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180858</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012;2012:595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">23233640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis:A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36697326</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic:overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033715</ArticleId><ArticleId IdType="pubmed">33609196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau:A population-based autopsy study. Ann Med. 2008;40(3):232&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18382889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30336828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez E, Gallego-Delgado M, Guzzo-Merello G, De Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26224076</ArticleId></ArticleIdList></Reference><Reference><Citation>Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis. Circ Cardiovasc Imaging. 2016;9(8):e005066.</Citation><ArticleIdList><ArticleId IdType="pubmed">27511979</ArticleId></ArticleIdList></Reference><Reference><Citation>Castan&#xf5; A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2595&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26224073</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldhagen P, Berg S, Lund LH, S&#xf6;rensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2021;289(6):895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248398</ArticleId><ArticleId IdType="pubmed">33274477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy:further analyses from ATTR-ACT. JACC Heart Fail. 2021;9(2):115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33309574</ArticleId></ArticleIdList></Reference><Reference><Citation>Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212550</ArticleId></ArticleIdList></Reference><Reference><Citation>Abstract 16852:A Simple Voltage/Mass Index Improves Diagnosis of Cardiac Amyloidosis in Patients With Unexplained Left Ventricular &#x201c;Hypertrophy&#x201d;:An Electrocardiographic and Echocardiographic Study of More Than 500 Patients. Circulation [Internet] 2010;122((Suppl. 21)) [cited 2024 Aug 22] Disponible en: https://www.ahajournals.org/doi/10.1161/circ.122.suppl_21. A16852 .</Citation></Reference><Reference><Citation>Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses:Disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19752327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Kang L, Tian Z, Chen W, Guo W, Xu J, et al. Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2011;16(1):25&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6932607</ArticleId><ArticleId IdType="pubmed">21251130</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A, Bauersachs J, Bengel F, B&#xfc;chel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis:position statement of the German Cardiac Society (DGK) Clin Res Cardiol. 2021;110((4)):479&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055575</ArticleId><ArticleId IdType="pubmed">33459839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A, et al. Are classic predictors of voltage valid in cardiac amyloidosis?A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27093686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli F, Vignini E, Martone R, Perlini S, Mussinelli R, Sabena A, et al. Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis. Circ Heart Fail. 2020;13(3):E006619.</Citation><ArticleIdList><ArticleId IdType="pubmed">32164434</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, et al. Low QRS voltages in cardiac amyloidosis:clinical correlates and prognostic value. JACC CardioOncol. 2022;4(4):458&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700257</ArticleId><ArticleId IdType="pubmed">36444225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(3):271&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6932192</ArticleId><ArticleId IdType="pubmed">23714086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9((6-7)):617&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350331</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P, Karp K, Bjerle P, Olofsson BO. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Heart. 1984;51(6):658&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC481569</ArticleId><ArticleId IdType="pubmed">6329251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez E, Gagliardi C, Dominguez F, Quarta CC, De Haro-Del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis:disproving myths. Eur Heart J. 2017;38((24)):1895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">28329248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, et al. Electrophysiological manifestations of cardiac amyloidosis:JACC:CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(4):506&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543134</ArticleId><ArticleId IdType="pubmed">34729522</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30(4):1046&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9316537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9578896</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009;104(7):990&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19766769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Labib SB, Shah SP. Electrocardiogram criteria to diagnose cardiac amyloidosis in men with a bundle branch block. Am J Cardiol. 2021;146:89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33529617</ArticleId></ArticleIdList></Reference><Reference><Citation>Alreshq R, Tugal D, Siddiqi O, Ruberg F. Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis:A systematic review. Pacing Clin Electrophysiol. 2021;44(12):2092&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34632598</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13(2):383&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26400855</ArticleId></ArticleIdList></Reference><Reference><Citation>Namdar M, Steffel J, Jetzer S, Schmied C, Hrlimann D, Camici GG, et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and fabry disease. Am J Cardiol. 2012;109(4):587&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105784</ArticleId></ArticleIdList></Reference><Reference><Citation>Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301598</ArticleId><ArticleId IdType="pubmed">25411195</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan D, Collier P, Thavendiranathan P, Popovi&#x107; ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22865865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SP, Park JB, Kim HK, Kim YJ, Grogan M, Sohn DW. Contemporary imaging diagnosis of cardiac amyloidosis. J Cardiovasc Imaging. 2019;27(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358430</ArticleId><ArticleId IdType="pubmed">30701710</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger-Roll&#xe9; A, Cariou E, Rguez K, Fournier P, Lavie-Badie Y, Blanchard V, et al. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart. 2020;7(2):e001346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555098</ArticleId><ArticleId IdType="pubmed">33051335</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmiero G, Rubino M, Monda E, Caiazza M, D'urso L, Carlomagno G, et al. Global left ventricular myocardial work efficiency in heart failure patients with cardiac amyloidosis:pathophysiological implications and role in differential diagnosis. J Cardiovasc Echogr. 2021;31((3)):157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8603776</ArticleId><ArticleId IdType="pubmed">34900551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2 - Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14(7):e000029.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis:A systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897958</ArticleId><ArticleId IdType="pubmed">27267362</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed IS, Glockner JF, Feng DL, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">20159642</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho FP de, Erthal F, Azevedo CF. The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis. Magn Reson Imaging Clin N Am. 2019;27(3):453&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">31279449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Oda S, Kidoh M, Hayashi H, Takashio S, Usuku H, et al. Cardiac MRI T1 and T2 mapping as a quantitative imaging biomarker in transthyretin amyloid cardiomyopathy. Acad Radiol. 2024;31(2):514&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">37775448</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 2 of 2&#x2013;Evidence base and standardized methods of imaging. J Nuclear Cardiol. 2019;26(6):2065&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">31468376</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196911</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12((9)):e006075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736650</ArticleId><ArticleId IdType="pubmed">31480867</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed A, Dorbala S. Current status of radionuclide imaging of transthyretin cardiac amyloidosis. Cardiol Clin. 2023;41(2):217&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11140431</ArticleId><ArticleId IdType="pubmed">37003679</ArticleId></ArticleIdList></Reference><Reference><Citation>Meristoudis G, Ilias I, Keramida G. Potential diagnostic pitfalls of bone scintigraphy in transthyretin-related amyloidosis. World J Nucl Med. 2020;19(03):313&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745849</ArticleId><ArticleId IdType="pubmed">33354195</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad JM, Ahmed AI, Han Y, Saeed S, Pournazari P, Al-Mallah MH. 99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis:a review of current and future directions. Heart Fail Rev. 2022;27(5):1493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">34709500</ArticleId></ArticleIdList></Reference><Reference><Citation>Embry-Dierson M, Farrell MB, Schockling E, Warren J, Jerome S. Cardiac amyloidosis imaging, Part 1:amyloidosis etiology and image acquisition. J Nucl Med Technol. 2023;51(2):83&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268319</ArticleId></ArticleIdList></Reference><Reference><Citation>Schockling EJ, Farrell MB, Embry-Dierson M, Warren J, Jerome S. Cardiac amyloidosis imaging, Part 2:quantification and technical considerations. J Nucl Med Technol. 2023;51(2):90&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis:a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148180</ArticleId><ArticleId IdType="pubmed">31607664</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerome S, Farrell MB, Warren J, Embry-Dierson M, Schockling EJ. Cardiac amyloidosis imaging, Part 3:interpretation, diagnosis, and treatment. J Nucl Med Technol. 2023;51(2):102&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268322</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph V, Julien HM, Bravo PE. Radionuclide imaging of cardiac amyloidosis. PET Clin. 2021;16(2):285&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33589384</ArticleId></ArticleIdList></Reference><Reference><Citation>Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. 99mTc bone-avid tracer cardiac scintigraphy:role in noninvasive diagnosis of transthyretin cardiac amiloidosis. Radiology. 2023;306(2):e221082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885342</ArticleId><ArticleId IdType="pubmed">36537896</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate:a test in evolution. JACC Cardiovasc Imaging. 2021;14(6):1221&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113330</ArticleId><ArticleId IdType="pubmed">33221204</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis:A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060056</ArticleId><ArticleId IdType="pubmed">33825853</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Glob Heart. 2023;18(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10607607</ArticleId><ArticleId IdType="pubmed">37901600</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27143678</ArticleId></ArticleIdList></Reference><Reference><Citation>Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">31302046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CC, Chang WT, Lin YH, Tzeng BH, Chao TH, Hung CL, et al. 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis. Acta Cardiol Sin. 2023;39(4):511&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10346051</ArticleId><ArticleId IdType="pubmed">37456934</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice:A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020;28:100519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191222</ArticleId><ArticleId IdType="pubmed">32373710</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure:a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">35150240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Hueso R, Salamanca-Bautista P, Quesada-Sim&#xf3;n MA, Yun S, Conde-Martel A, Morales-Rull JL, et al. Estimating the prevalence of cardiac amyloidosis in old patients with heart failure&#x2013;barriers and opportunities for improvement:the PREVAMIC study. J Clin Med. 2023;12((6))</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10057876</ArticleId><ArticleId IdType="pubmed">36983274</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557425</ArticleId><ArticleId IdType="pubmed">31170802</ArticleId></ArticleIdList></Reference><Reference><Citation>Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis:A review. J Am Heart Assoc. 2012;1((2)):e000364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487372</ArticleId><ArticleId IdType="pubmed">23130126</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis:A treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. 2021;31(1):59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297649</ArticleId><ArticleId IdType="pubmed">31889610</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, et al. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy:early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023;10(1):397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871707</ArticleId><ArticleId IdType="pubmed">36259276</ArticleId></ArticleIdList></Reference><Reference><Citation>Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">38866445</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly JP, Hanna M. Cardiac amyloidosis:An update on diagnosis and treatment. Cleve Clin J Med. 2017;84:12&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29257735</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis:Current and emerging management strategies. JACC CardioOncol. 2021;3(4):488&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543085</ArticleId><ArticleId IdType="pubmed">34729521</ArticleId></ArticleIdList></Reference><Reference><Citation>Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(4):351&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">32327068</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrey S, Pollak A, Skinner M, Falk RH, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis:evidence for atrial electromechanical dissociation. Br Heart J. 1995;74(5):541&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC484078</ArticleId><ArticleId IdType="pubmed">8562243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari Syed, Khan Sz, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis:a review. J Card Fail. 2023;29(1):76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">36122817</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020;22(2):259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">32031230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9542906</ArticleId><ArticleId IdType="pubmed">35650018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari S, Barakat AF, Eisele YS, Nieves R, Jain S, Saba S, et al. Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy. Circulation. 2021;143(13):1335&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">33779268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli F, Tini G, Russo D, Emdin M, Del Franco A, Vergaro G, et al. Arterial thrombo-embolic events in cardiac amyloidosis:a look beyond atrial fibrillation. Amyloid. 2021;28(1):12&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32981389</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895&#x2013;e1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani LR, De Los Santos J, Driggin E, Kogan R, Helmke S, Goldsmith J, et al. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis:comparison of thromboembolic events and major bleeding. Amyloid. 2021;28(1):30&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018530</ArticleId><ArticleId IdType="pubmed">32814468</ArticleId></ArticleIdList></Reference><Reference><Citation>Laptseva N, Rossi VA, Sudano I, Schwotzer R, Ruschitzka F, Flammer AJ, et al. Arrhythmic manifestations of cardiac amyloidosis:challenges in risk stratification and clinical management. J Clin Med. 2023;2581;12(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10095126</ArticleId><ArticleId IdType="pubmed">37048664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Holmes BB, Huang S, Lugo R, Aboud A Al, Goodman S, et al. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace. 2020;22(8):1216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32514579</ArticleId></ArticleIdList></Reference><Reference><Citation>John R. Arrhythmias in cardiac amyloidosis. J Innov Card Rhythm Manag. 2018;9(3):3051&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252761</ArticleId><ArticleId IdType="pubmed">32477799</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death:Executive Summary. Circulation. 2018;138(13):e210&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29084733</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Arbelo E, Barriales-Villa R, et al. 2023 ESC Guidelines for the management of cardiomyopathies:Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) Eur Heart J. 2023;44(37):3503&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2022;24(1):71&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">34455427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis:challenges in risk stratification and treatment. Can J Cardiol. 2020;36(3):416&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32145868</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10757426</ArticleId><ArticleId IdType="pubmed">37888916</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, et al. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy:the Boston University Amyloidosis Center experience. Amyloid. 2022;29(2):71&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258521</ArticleId><ArticleId IdType="pubmed">35083944</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145929</ArticleId></ArticleIdList></Reference><Reference><Citation>Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048553</ArticleId><ArticleId IdType="pubmed">33070419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">38197816</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25(3):147&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30660664</ArticleId></ArticleIdList></Reference><Reference><Citation>aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis:an observational study. Drug Des Devel Ther. 2015;9:6319&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675646</ArticleId><ArticleId IdType="pubmed">26673202</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo AVS, Schwartzmann PV, de Gusm&#xe3;o BM, de Melo MDT, Coelho-Filho OR. Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol. 2020;21(5):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181421</ArticleId><ArticleId IdType="pubmed">32328845</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1):e2018022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841939</ArticleId><ArticleId IdType="pubmed">29531659</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladini G, Sch&#xf6;nland S, Merlini G, Milani P, Jaccard A, Bridoux F, et al. The management of light chain (AL) amyloidosis in Europe:clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9876983</ArticleId><ArticleId IdType="pubmed">36697388</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010532</ArticleId></ArticleIdList></Reference><Reference><Citation>Oe Y, Soma J, Sato H, Ito S. Heavy chain deposition disease:An overview. Clin Exp Nephrol. 2013;17(6):771&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihne S, Morbach C, Obici L, Palladini G, St&#xf6;rk S. Amyloidosis in heart failure. Curr Heart Fail Rep. 2019;16(6):285&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">31782077</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131635</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85(3):232&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843113</ArticleId><ArticleId IdType="pubmed">20194151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82(8):1501&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar SV. Multiple myeloma:2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291298</ArticleId><ArticleId IdType="pubmed">27291302</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Bitterman H. Images in clinical medicine Amyloid Purpura. N Engl J Med. 2007;2406;356(23)</Citation><ArticleIdList><ArticleId IdType="pubmed">17554122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25779559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">34192431</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Dispenzieri A, Sanchorawala V, Sch&#xf6;nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutani D, Lentzsch S. Diagnosis and management of systemic light chain AL amyloidosis. Pharmacol Ther. 2020;214:107612.</Citation><ArticleIdList><ArticleId IdType="pubmed">32562825</ArticleId></ArticleIdList></Reference><Reference><Citation>Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">31578202</ArticleId></ArticleIdList></Reference><Reference><Citation>Decotto S, Villanueva E, de Arenaza P&#xe9;rez D, Nucifora EM, Aguirre MA, Posadas-Mart&#xed;nez ML, et al. Heart transplantation in amyloidosis. Clinical and imaging manifestations. Arch Cardiol Mex. 2022;92(3):320&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262297</ArticleId><ArticleId IdType="pubmed">34619747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation:A 10-year update. J Heart Lung Transplant. 2016;35(1):1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26776864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsich E, Singh TP, Cherikh WS, Harhay MO, Hayes D, Perch M, et al. The International thoracic organ transplant registry of the international society for heart and lung transplantation:Thirty-ninth adult heart transplantation report&#x2013;2022;focus on transplant for restrictive heart disease. J Heart Lung Transplant. 2022;41(10):1366&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281817</ArticleId><ArticleId IdType="pubmed">36031520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. Vol. 22, Heart Failure Reviews. Springer New York LLC. 2017:317&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28281017</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MK, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15(3):650&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25648766</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilas-Boas M do C, Rocha AP, Cardoso MN, Fernandes JM, Coelho T, Cunha JPS. Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis. Front Neurol. 2020;11:605282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719818</ArticleId><ArticleId IdType="pubmed">33329366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta NR. Care of patients with transthyretin amyloidosis:the roles of nutrition, supplements, exercise, and mental health. Am J Cardiol. 2022;185:S35&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">36549789</ArticleId></ArticleIdList></Reference><Reference><Citation>Argir&#xf2; A, Silverii MV, Burgisser C, Fattirolli F, Baldasseroni S, di Mario C, et al. Serial changes in cardiopulmonary exercise testing parameters in untreated patients with transthyretin cardiac amyloidosis. Can J Cardiol. 2024;40(3):364&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">37793568</ArticleId></ArticleIdList></Reference><Reference><Citation>Banydeen R, Monfort A, Inamo J, Neviere R. Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis. Front Cardiovasc Med. 2022;9:898033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207317</ArticleId><ArticleId IdType="pubmed">35734274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini S, Baldasseroni S, Fattirolli F, Silverii MV, Piccioli L, Perfetto F, et al. Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients. Intern Emerg Med. 2021;16(3):653&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32918156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis. Am J Cardiol. 2019;124(1):122&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556126</ArticleId><ArticleId IdType="pubmed">31053293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantone A, Serenelli M, Sanguettoli F, Maio D, Fabbri G, Dal Passo B, et al. Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy:a systematic review and meta-analysis. ESC Heart Fail. 2023;10(4):2740&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10375073</ArticleId><ArticleId IdType="pubmed">37264762</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverii MV, Argir&#xf2; A, Baldasseroni S, Fumagalli C, Zampieri M, Guerrieri L, et al. Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis. Intern Emerg Med. 2023;18(2):585&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36396841</ArticleId></ArticleIdList></Reference><Reference><Citation>Banydeen R, Eggleston R, Deney A, Monfort A, Ryu JH, Vergaro G, et al. Risk stratification in transthyretin cardiac amyloidosis:the added value of lung spirometry. J Clin Med. 2023;3684;12(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10254011</ArticleId><ArticleId IdType="pubmed">37297878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalia T, Acharya P, Chan WC, Sauer AJ, Weidling R, Fritzlen JG, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34280522</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank AM, Horton J, Fleg JL, Fonarow GC, Keteyian S, Goldberg L, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients:Results from Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training. Circ Heart Fail. 2012;5(5):579&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732187</ArticleId><ArticleId IdType="pubmed">22773109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction:The role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8(2):286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771713</ArticleId><ArticleId IdType="pubmed">25344549</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemmensen TS, Soerensen J, Hansson NH, Tolbod LP, Harms HJ, Eiskj&#xe6;r H, et al. Myocardial oxygen consumption and efficiency in patients with cardiac amyloidosis. J Am Heart Assoc. 201;7(21):e009974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404209</ArticleId><ArticleId IdType="pubmed">30571379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapezzi C, Milandri A, Lorenzini M. The complex interplay between systolic and diastolic function at rest and during exercise in heart failure:the case of cardiac amyloidosis. Eur J Heart Fail. 2017;19(11):1466&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28905503</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis:A systematic review and meta-analysis. Hellenic J Cardiol. 2019;60(6):375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30742933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahashi T, Arita T, Yamaji K, Inoue K, Yokota T, Hoshii Y, et al. Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. Int J Cardiol. 2014;176(3):753&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">31109193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122i mutations and wild-type transthyretin transthyretin cardiac amyloid study (TRACS) Circ Heart Fail. 2011;4(2):121&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939845</ArticleId><ArticleId IdType="pubmed">21191093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy:The Transthyretin Amyloidosis Cardiac Study (TRACS) Am Heart J. 2012;164(2):222&#x2013;228.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22877808</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, et al. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) Am J Cardiol. 2021;148:146&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33667442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin J, Steidley DE, Carlsson M, Mohlim O, Maurer MS. Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis. J Card Fail. 2018;24(8):504&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372291</ArticleId><ArticleId IdType="pubmed">30010028</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis. Circ Cardiovasc Imaging. 2018;11(5):e006588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963522</ArticleId><ArticleId IdType="pubmed">29752392</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng KY, Loungani RS, Rao VN, Patel CB, Khouri MG, Felker GM, et al. Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2019;1(2):273&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352120</ArticleId><ArticleId IdType="pubmed">34396189</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27585505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">29048471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675680</ArticleId><ArticleId IdType="pubmed">22331953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Reilly MM, Coats CJ, Cooper R, Cox H, Coyne MRE, et al. Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis:an expert opinion and consensus on Best Practice in Ireland and the UK. Adv Ther. 2022;39(6):2292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122857</ArticleId><ArticleId IdType="pubmed">35419651</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F, Bisogni G, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy:a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15(1):348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734774</ArticleId><ArticleId IdType="pubmed">33317601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239528</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease.</ArticleTitle><Pagination><StartPage>1076</StartPage><EndPage>1084</EndPage><MedlinePgn>1076-1084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002425</ELocationID><Abstract><AbstractText Label="BACKGROUND">High-risk features in stage II colon cancer worsen survival and serve as an impetus for adjuvant chemotherapy. Limited data exist on the effect of multiple high-risk features on survival.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to compare the survival of 0, 1, or multiple high-risk features in stage II to stage III colon cancer.</AbstractText><AbstractText Label="DESIGN">Patients with stage II and III colon cancer diagnosed between 2010 and 2016 were identified using the Survival, Epidemiology, and End Results database. Patients with stage II colon cancer were then classified according to the presence of 0, 1, or 2 or more of the following high-risk features: pathologic T4, perineural invasion, fewer than 12 lymph nodes assessed, or poor histologic differentiation. Overall survival and cause-specific survival were calculated. Each group was then stratified on the basis of whether chemotherapy was given.</AbstractText><AbstractText Label="SETTINGS">This study used the Survival, Epidemiology, and End Results database (2010-2016).</AbstractText><AbstractText Label="PATIENTS">Patients who had stage II or III colon cancer were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome measures were 5-year overall survival and cause-specific survival.</AbstractText><AbstractText Label="RESULTS">A total of 65,831 patients were studied. Of these, 18,056 patients with stage II cancer had 0 high-risk features, 9426 had 1 high-risk feature, and 3503 had 2 or more high-risk features. There were 34,842 patients diagnosed with stage III disease. The 5-year overall survival and cause-specific survival for patients with stage II cancer with 2 or more high-risk features (49.2%, 59.5%) were lower than those without high-risk features (74.9%, 90.7%), with 1 high-risk feature (67.1%, 82.4%), or stage III disease (59.1%, 68.1%; p &lt; 0.05). Although chemotherapy is associated with improved cause-specific survival in stage III disease, it is associated with worse cause-specific survival in patients with stage II disease.</AbstractText><AbstractText Label="LIMITATIONS">This study being a retrospective database analysis is the main limitation. Also, lymphovascular invasion, margin status, and clinical obstruction or perforation were absent from the dataset.</AbstractText><AbstractText Label="CONCLUSIONS">Multiple high-risk features in stage II colon cancer predict worse survival than lymph node metastasis. Chemotherapy is associated with adverse cause-specific survival in patients with stage II disease. Further study into this group should focus on the type and duration of adjuvant therapy and biological features of these tumors. See Video Abstract at http://links.lww.com/DCR/B929 .</AbstractText><AbstractText Label="MLTIPLES CARACTERSTICAS DE ALTO RIESGO PARA EL CARCINOMA DE COLON EN ESTADIO II PRESAGIAN PEOR SUPERVIVENCIA QUE LA ENFERMEDAD EN ESTADIO III">ANTECEDENTES:Las caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II empeoran la supervivencia y sirven como impulso para la quimioterapia adyuvante. Existen datos limitados sobre el efecto de m&#xfa;ltiples caracter&#xed;sticas de alto riesgo en la supervivencia.OBJETIVO:Comparar la supervivencia de cero, una o m&#xfa;ltiples caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II con la enfermedad en estadio III.DISE&#xd1;O:Los pacientes con c&#xe1;ncer de colon en estadio II y III diagnosticados entre 2010 y 2016 se identificaron mediante la base de datos de supervivencia, epidemiolog&#xed;a y resultados finales. Luego, los pacientes en etapa II se clasificaron seg&#xfa;n la presencia de cero, 1 o 2+ de las siguientes caracter&#xed;sticas de alto riesgo: T4 patol&#xf3;gico, invasi&#xf3;n perineural, menos de 12 ganglios linf&#xe1;ticos evaluados (&lt; 12 ganglios linf&#xe1;ticos) o mala diferenciaci&#xf3;n histol&#xf3;gica. Se calcul&#xf3; la supervivencia observada y espec&#xed;fica de la causa. Luego, cada grupo se estratific&#xf3; en funci&#xf3;n de si se administr&#xf3; quimioterapia.ESCENARIO:Este estudio utiliz&#xf3; la base de datos de supervivencia, epidemiolog&#xed;a y resultados finales, 2010-2016.PACIENTES:Los pacientes ten&#xed;an c&#xe1;ncer de colon en estadio II o III.PRINCIPALES MEDIDAS DE RESULTADO:La medida principal fue la supervivencia observada a 5 a&#xf1;os y la supervivencia por causa espec&#xed;fica.RESULTADOS:Se estudiaron un total de 65,831 pacientes. 18,056 pacientes estaban en estadio II sin caracter&#xed;sticas de alto riesgo, 9.426 con 1 caracter&#xed;stica de alto riesgo y 3.503 con 2+ caracter&#xed;sticas de alto riesgo. Hubo 34.842 pacientes a los que se les diagnostic&#xf3; enfermedad en estadio III. La supervivencia observada a los 5 a&#xf1;os y la supervivencia espec&#xed;fica de la causa para los pacientes con c&#xe1;ncer en estadio II con 2+ caracter&#xed;sticas de alto riesgo (49.2 %, 59.5 %) fueron m&#xe1;s bajas, en comparaci&#xf3;n con aquellos sin caracter&#xed;sticas de alto riesgo (74.9 %, 90.7 %), con 1 caracter&#xed;stica de alto riesgo (67.1 %, 82.4 %) o enfermedad en estadio III (59.1 %, 68.1 %) (p &lt; 0.05). Si bien la quimioterapia se asocia con una mejor supervivencia por causa espec&#xed;fica en la enfermedad en estadio III, se asocia con una peor supervivencia por causa espec&#xed;fica en pacientes con enfermedad en estadio II.LIMITACIONES:Este es un an&#xe1;lisis de base de datos retrospectivo. La invasi&#xf3;n linfovascular, el estado de los m&#xe1;rgenes y la obstrucci&#xf3;n o perforaci&#xf3;n cl&#xed;nicas estaban ausentes en la base de datos.CONCLUSIONES:M&#xfa;ltiples caracter&#xed;sticas de alto riesgo en el c&#xe1;ncer de colon en estadio II predicen una peor supervivencia que la met&#xe1;stasis en los ganglios linf&#xe1;ticos. La quimioterapia se asocia con una supervivencia espec&#xed;fica de causa adversa en pacientes con enfermedad en estadio II. El estudio adicional de este grupo deber&#xe1; centrarse en el tipo y la duraci&#xf3;n de la terapia adyuvante y las caracter&#xed;sticas biol&#xf3;gicas de estos tumores. Consulte Video Resumen en http://links.lww.com/DCR/B929 . (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajirawala</LastName><ForeName>Luv N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herritt</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Morgan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinger</LastName><ForeName>Aaron L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orangio</LastName><ForeName>Guy R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kurt G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Section of Colon and Rectal Surgery, Department of Surgery, Louisiana State University School of Medicine New Orleans, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="Y">Carcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239528</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002425</ArticleId><ArticleId IdType="pii">00003453-202308000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation></Reference><Reference><Citation>Andr&#xe9; T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176&#x2013;4187.</Citation></Reference><Reference><Citation>Wells KO, Hawkins AT, Krishnamurthy DM, et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest. Dis Colon Rectum. 2017;60:15&#x2013;21.</Citation></Reference><Reference><Citation>Chang CL, Yuan KS, Wu ATH, Wu SY. Adjuvant therapy for high-risk stage II or III colon adenocarcinoma: a propensity score-matched, nationwide, population-based cohort study. Cancers (Basel). 2019;11:E2003.</Citation></Reference><Reference><Citation>Artac M, Turhal NS, Kocer M, et al. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100:143&#x2013;148.</Citation></Reference><Reference><Citation>Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121:527&#x2013;534.</Citation></Reference><Reference><Citation>Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51:503&#x2013;507.</Citation></Reference><Reference><Citation>Romiti A, Roberto M, Marchetti P, et al. Study of histopathologic parameters to define the prognosis of stage II colon cancer. Int J Colorectal Dis. 2019;34:905&#x2013;913.</Citation></Reference><Reference><Citation>Park JS, Chon HJ, Jeung HC, et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol. 2016;142:2051&#x2013;2059.</Citation></Reference><Reference><Citation>Amri R, England J, Bordeianou LG, Berger DL. Risk stratification in patients with stage II colon cancer. Ann Surg Oncol. 2016;23:3907&#x2013;3914.</Citation></Reference><Reference><Citation>Hatano S, Ishida H, Ishibashi K, Kumamoto K, Haga N, Miura I. Identification of risk factors for recurrence in high-risk stage II colon cancer. Int Surg. 2013;98:114&#x2013;121.</Citation></Reference><Reference><Citation>Skancke M, Arnott SM, Amdur RL, Siegel RS, Obias VJ, Umapathi BA. Lymphovascular invasion and perineural invasion negatively impact overall survival for stage II adenocarcinoma of the colon. Dis Colon Rectum. 2019;62:181&#x2013;188.</Citation></Reference><Reference><Citation>Babcock BD, Aljehani MA, Jabo B, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25:1980&#x2013;1985.</Citation></Reference><Reference><Citation>Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg. 2017;37:42&#x2013;49.</Citation></Reference><Reference><Citation>Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol. 2016;40:103&#x2013;112.</Citation></Reference><Reference><Citation>Yang Y, Huang X, Sun J, et al. Prognostic value of perineural invasion in colorectal cancer: a meta-analysis. J Gastrointest Surg. 2015;19:1113&#x2013;1122.</Citation></Reference><Reference><Citation>Yun JA, Kim HC, Kim SH, et al. Prognostic significance of perineural invasion in stage IIA colon cancer. ANZ J Surg. 2016;86:1007&#x2013;1013.</Citation></Reference><Reference><Citation>Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009;27:5131&#x2013;5137.</Citation></Reference><Reference><Citation>Mayo E, Llanos AA, Yi X, Duan SZ, Zhang L. Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. Histopathology. 2016;69:230&#x2013;238.</Citation></Reference><Reference><Citation>Oliphant R, Horgan PG, Morrison DS, McMillan DC; West of Scotland Colorectal Cancer Managed Clinical Network. Validation of a modified clinical risk score to predict cancer-specific survival for stage II colon cancer. Cancer Med. 2015;4:84&#x2013;89.</Citation></Reference><Reference><Citation>Souglakos J, Boukovinas I, Kakolyris S, et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol. 2019;30:1304&#x2013;1310.</Citation></Reference><Reference><Citation>Lee DW, Kim KJ, Han SW, et al. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol. 2015;22:187&#x2013;194.</Citation></Reference><Reference><Citation>Lee VWK, Chan KF. Tumor budding and poorly-differentiated cluster in prognostication in stage II colon cancer. Pathol Res Pract. 2018;214:402&#x2013;407.</Citation></Reference><Reference><Citation>Bullock MD, Pickard K, Mitter R, et al. Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget. 2015;6:7262&#x2013;7279.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34882630</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Perianal Fistula After Ileoanal Pouch in Patients With Ulcerative Colitis: A Review of 475 Patients Operated on at a Major IBD Center.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>82</EndPage><MedlinePgn>76-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002114</ELocationID><Abstract><AbstractText Label="BACKGROUND">Ileoanal pouch anastomosis is the surgical treatment of choice for patients with intractable ulcerative colitis. Perianal disease is a feature that is often present in Crohn's disease and infrequently in ulcerative colitis.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study is to identify the incidence and factors associated with the development of postoperative perianal fistula in patients undergoing ileoanal pouch anastomosis for ulcerative colitis.</AbstractText><AbstractText Label="DESIGN">A prospectively collected database at the time of surgery with subsequent follow-up was utilized.</AbstractText><AbstractText Label="SETTING">The study was conducted at a high-volume single institution.</AbstractText><AbstractText Label="PATIENTS">We studied a series of 475 consecutive patients with preoperative diagnosis of ulcerative colitis who underwent ileoanal pouch anastomosis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The incidence of postoperative perianal fistula and the factors correlating with its development were primary outcome measures of the study.</AbstractText><AbstractText Label="RESULTS">The overall number of patients developing perianal fistulas was 44 of 475 (9%). Eleven patients with perianal fistula (25%) required return to ileostomy, of which 7 had pouch excision. Patients who developed a postoperative perianal fistula had a younger age at the onset of disease, had a lower age at index surgery, and were more likely to be subsequently classified as indeterminate colitis or Crohn's disease. Patients developing perianal fistulas were also more likely to develop partial dehiscence or stricture of the ileoanal anastomosis.</AbstractText><AbstractText Label="LIMITATIONS">This study spans nearly 40 years during which the surgical procedure evolved.</AbstractText><AbstractText Label="CONCLUSIONS">Young age at the onset of disease, lower age at surgery, and postoperative diagnosis of Crohn's disease and indeterminate colitis were the factors correlating with perianal fistulas. Delayed healing of the ileoanal anastomosis with partial separation and/or stricture also correlated with the onset of perianal fistulas. The severity of rectal inflammation at the time of surgery or the presence of stapled versus handsewn anastomosis did not correlate with the development of perianal fistulas. See Video Abstract at http://links.lww.com/DCR/B705.</AbstractText><AbstractText Label="FSTULA PERIANAL POSTERIOR A RESERVORIO ILEOANAL EN PACIENTES CON COLITIS ULCERATIVA UNA REVISIN DE PACIENTES OPERADOS EN UN CENTRO PRINCIPAL DE EII">ANTECEDENTES:El reservorio ileoanal es el tratamiento quir&#xfa;rgico de elecci&#xf3;n para los pacientes con colitis ulcerativa intratable. La enfermedad perianal es una caracter&#xed;stica que a menudo est&#xe1; presente en la enfermedad de Crohn y con poca frecuencia en la colitis ulcerativa.OBJETIVO:El objetivo del estudio es identificar la incidencia y los factores asociados con el desarrollo de f&#xed;stula perianal posoperatoria en pacientes sometidos a reservorio ileoanal por colitis ulcerativa.DISE&#xd1;O:Base de datos recopilada prospectivamente en el momento de la cirug&#xed;a con seguimiento subsecuente.ENTORNO CL&#xcd;NICO:El estudio se llev&#xf3; a cabo en una &#xfa;nica instituci&#xf3;n de gran volumen.PACIENTES:Estudiamos una serie de 475 pacientes consecutivos con diagn&#xf3;stico preoperatorio de colitis ulcerativa a los que se les realiz&#xf3; reservorio ileoanal.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:La incidencia de f&#xed;stula perianal posoperatoria y los factores que se correlacionan con su desarrollo fueron las principales medidas de resultado del estudio.RESULTADOS:El n&#xfa;mero total de pacientes que desarrollaron f&#xed;stulas perianales fue 44 de 475 (9%). Once pacientes con f&#xed;stula perianal (25%) requirieron volver a la ileostom&#xed;a, de los cuales 7 tuvieron resecci&#xf3;n del reservorio. Los pacientes que desarrollaron f&#xed;stula perianal posoperatoria ten&#xed;an edad m&#xe1;s temprana al inicio de la enfermedad, menor edad en el momento de la cirug&#xed;a inicial y ten&#xed;an m&#xe1;s probabilidades de ser clasificados posteriormente como colitis indeterminada o enfermedad de Crohn. Los pacientes que desarrollaron f&#xed;stulas perianales tambi&#xe9;n fueron m&#xe1;s propensos a desarrollar dehiscencia parcial o estenosis de la anastomosis ileoanal.LIMITACIONES:Este estudio abarca casi 40 a&#xf1;os durante los cuales ha evolucionado el procedimiento quir&#xfa;rgico.CONCLUSIONES:Edad temprana al inicio de la enfermedad, menor edad al momento de la cirug&#xed;a, diagn&#xf3;stico postoperatorio de enfermedad de Crohn y colitis indeterminada fueron los factores que se correlacionaron con las f&#xed;stulas perianales. El retraso en la cicatrizaci&#xf3;n de la anastomosis ileoanal con separaci&#xf3;n parcial y/o estenosis tambi&#xe9;n se correlacion&#xf3; con la aparici&#xf3;n de f&#xed;stulas perianales. La gravedad de la inflamaci&#xf3;n rectal en el momento de la cirug&#xed;a o la presencia de anastomosis con grapas versus anastomosis manual no se correlacion&#xf3; con el desarrollo de f&#xed;stulas perianales. Consulte Video Resumen en http://links.lww.com/DCR/B705.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heimann</LastName><ForeName>Tomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Colorectal Surgery, The Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Santosh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Slater</LastName><ForeName>Gary I</ForeName><Initials>GI</Initials></Author><Author ValidYN="Y"><LastName>Kurtz</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D057405">Webcast</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039021" MajorTopicYN="N">Colonic Pouches</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007081" MajorTopicYN="N">Ileostomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019449" MajorTopicYN="N">Pouchitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="N">Rectal Fistula</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>17</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34882630</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002114</ArticleId><ArticleId IdType="pii">00003453-202201000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crohn B, Ginzburg L, Oppenheimer GD. Regional ileitis. JAMA. 1932;99:1323.</Citation></Reference><Reference><Citation>Ravitch MM, Sabiston DC Jr. Anal ileostomy with preservation of the sphincter; a proposed operation in patients requiring total colectomy for benign lesions. Surg Gynecol Obstet. 1947;84:1095&#x2013;1099.</Citation></Reference><Reference><Citation>Heimann T, Beck AR, Greenstein AJ. Familial polyposis coli. Management by total colectomy with preservation of continence. Arch Surg. 1978;113:1104&#x2013;1106.</Citation></Reference><Reference><Citation>Martin LW, LeCoultre C, Schubert WK. Total colectomy and mucosal proctectomy with preservation of continence in ulcerative colitis. Ann Surg. 1977;186:477&#x2013;480.</Citation></Reference><Reference><Citation>Heimann T. The endorectal pullthrough: surgical considerations. Mt Sinai J Med. 1980;47:606&#x2013;611.</Citation></Reference><Reference><Citation>Heimann T, Gelernt I, Bauer J, et al. Mucosal proctectomy without reservoir. Am J Surg. 1983;145:674&#x2013;677.</Citation></Reference><Reference><Citation>Heimann T, Kurtz RJ, Shen S, et al. Mucosal proctectomy and endorectal pullthrough using ultrasonic tissue fragmentation. Surg Forum. 1983;34:202&#x2013;203.</Citation></Reference><Reference><Citation>Heimann TM, Kurtz RJ, Shen S, Aufses AH Jr. Mucosal proctectomy using an ultrasonic scalpel. Am J Surg. 1984;147:803&#x2013;806.</Citation></Reference><Reference><Citation>IBM SPSS Statistics for Macintosh, Version 26.0. Armonk, NY; IBM Corp.</Citation></Reference><Reference><Citation>Nisar PJ, Kiran RP, Shen B, Remzi FH, Fazio VW. Factors associated with ileoanal pouch failure in patients developing early or late pouch-related fistula. Dis Colon Rectum. 2011;54:446&#x2013;453.</Citation></Reference><Reference><Citation>Shannon A, Eng K, Kay M, et al. Long-term follow up of ileal pouch anal anastomosis in a large cohort of pediatric and young adult patients with ulcerative colitis. J Pediatr Surg. 2016;51:1181&#x2013;1186.</Citation></Reference><Reference><Citation>Araki T, Okita Y, Fujikawa H, Inoue Y, Mohri Y, Kusunoki M. Full mucosal proctectomy initiated below the dentate line may prevent the development of a perianal fistula after ileal pouch-anal anastomosis for ulcerative colitis. Dig Surg. 2013;30:219&#x2013;224.</Citation></Reference><Reference><Citation>Fasen GS, Pandian TK, Pavey ES, Dozois EJ, Boostrom SY. Long-term outcome of IPAA in Patients presenting with fulminant ulcerative colitis: a matched cohort study. World J Surg. 2015;39:2590&#x2013;2594.</Citation></Reference><Reference><Citation>Tekkis PP, Fazio VW, Remzi F, Heriot AG, Manilich E, Strong SA. Risk factors associated with ileal pouch-related fistula following restorative proctocolectomy. Br J Surg. 2005;92:1270&#x2013;1276.</Citation></Reference><Reference><Citation>Choi YS, Kim DS, Lee DH, et al. Clinical characteristics and incidence of perianal diseases in patients with ulcerative colitis. Ann Coloproctol. 2018;34:138&#x2013;143.</Citation></Reference><Reference><Citation>Hamzaoglu I, Hodin RA. Perianal problems in patients with ulcerative colitis. Inflamm Bowel Dis. 2005;11:856&#x2013;859.</Citation></Reference><Reference><Citation>Fazio VW, Tekkis PP, Remzi F, et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg. 2003;238:605&#x2013;14; discussion 614.</Citation></Reference><Reference><Citation>Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn&#x2019;s disease: future directions. Gut. 2018;67:1181&#x2013;1194.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34759248</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Gracilis Flap Repair for Reoperative Rectovaginal Fistula.</ArticleTitle><Pagination><StartPage>113</StartPage><EndPage>117</EndPage><MedlinePgn>113-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002249</ELocationID><Abstract><AbstractText Label="BACKGROUND">Surgical treatment of recurrent rectovaginal fistulas is notoriously difficult. Placement of the gracilis muscle between the vagina and anus is an advanced technique used to close persistent fistulas. We have utilized this procedure for recalcitrant fistulas and hypothesized that a gracilis interposition would offer a good treatment option for patients with refractory rectovaginal fistulas, regardless of underlying etiology.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study was to investigate healing rates of gracilis interposition in patients with refractory rectovaginal fistulas.</AbstractText><AbstractText Label="DESIGN">Following institutional review board approval, a retrospective review of all adult female patients with a diagnosis of rectovaginal fistula between January 2009 and August 2020 was performed; those who underwent gracilis interposition for definitive fistula closure were included for analysis.</AbstractText><AbstractText Label="SETTINGS">The study was conducted at a colorectal surgery department at a tertiary center in the United States.</AbstractText><AbstractText Label="PATIENTS">All patients were adult females with a diagnosis of a rectovaginal fistula who underwent gracilis interposition for definitive closure.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Patient demographics, etiology of rectovaginal fistula, previous surgical intervention, presence of intestinal diversion, operative details, 30-day morbidity, recurrence of fistula, and time to recurrence. Fistula closure was defined as lack of clinical symptoms following stoma closure, negative fistula detection on gastrograffin enema' and absence of an internal opening at examination under anesthesia.</AbstractText><AbstractText Label="RESULTS">Twenty-two patients were included who had a median age of 43 years (range, 19-64 years) and median body mass index of 31&#x2009;kg/m 2 (range, 22-51). Median time between prior attempted surgical repair and gracilis surgery was 7 months (range, 3-17). The number of previously attempted repairs were 1-2 (n = 8), 3-4 (n = 9), and &gt; 4 (n = 5). The most recent attempted surgical repair was rectal advancement flap (n = 7), transperineal +/- Martius flap (n = 4), episioproctotomy (n = 3), transvaginal repair (n = 2), and other (n = 6). All patients had fecal diversion at the time of gracilis surgery. Thirty-day postoperative surgical site infection at the graft/donor site was 32% (n = 7). At a median follow-up of 22 months (range 2-62), fistula closure was 59% (n = 13). Gracilis interposition was successful in all inflammatory bowel disease patients.</AbstractText><AbstractText Label="LIMITATIONS">The study was limited by its retrospective nature.</AbstractText><AbstractText Label="CONCLUSIONS">Gracilis interposition is an effective operative technique for reoperative rectovaginal fistula closure. Patients should be counseled regarding the possibility of graft/donor site infection. See Video Abstract at http://links.lww.com/DCR/B763 .</AbstractText><AbstractText Label="REPARACIN CON COLGAJO DE GRACILIS PARA LA FSTULA RECTOVAGINAL REOPERATORIA">ANTECEDENTES:El tratamiento quir&#xfa;rgico de las f&#xed;stulas rectovaginales recurrentes es muy dif&#xed;cil. La colocaci&#xf3;n del m&#xfa;sculo gracilis entre la vagina y el ano es una t&#xe9;cnica avanzada que se utiliza para cerrar las f&#xed;stulas persistentes. Hemos utilizado este procedimiento para las f&#xed;stulas recalcitrantes y planteamos la hip&#xf3;tesis de que una interposici&#xf3;n del gracilis ofrecer&#xed;a una buena opci&#xf3;n de tratamiento para pacientes con f&#xed;stulas rectovaginales refractarias, independientemente de la etiolog&#xed;a subyacente.OBJETIVO:Investigar las tasas de curaci&#xf3;n de la interposici&#xf3;n del gracilis en pacientes con f&#xed;stulas rectovaginales refractarias.DISE&#xd1;O:Tras la aprobaci&#xf3;n de la junta de revisi&#xf3;n institucional, se realiz&#xf3; una revisi&#xf3;n retrospectiva de todas las pacientes adultas con un diagn&#xf3;stico de f&#xed;stula rectovaginal entre enero de 2009 y agosto de 2020; los que se sometieron a interposici&#xf3;n de gracilis para el cierre definitivo de la f&#xed;stula se incluyeron para el an&#xe1;lisis.AJUSTE:Departamento de cirug&#xed;a colorrectal de un centro terciario en Estados Unidos.PACIENTES:Todas las pacientes adultas con diagn&#xf3;stico de f&#xed;stula rectovaginal que se sometieron a interposici&#xf3;n de gracilis para cierre definitivo.PRINCIPALES MEDIDAS DE RESULTADO:datos demogr&#xe1;ficos del paciente, etiolog&#xed;a de la f&#xed;stula rectovaginal, intervenci&#xf3;n quir&#xfa;rgica previa, presencia de derivaci&#xf3;n intestinal, detalles quir&#xfa;rgicos, morbilidad a los 30 d&#xed;as, recurrencia de la f&#xed;stula y tiempo hasta la recurrencia. El cierre de la f&#xed;stula se defini&#xf3; como la ausencia de s&#xed;ntomas cl&#xed;nicos despu&#xe9;s del cierre del estoma, la detecci&#xf3;n negativa de la f&#xed;stula en el enema de gastrograffin y la ausencia de una abertura interna en el examen bajo anestesia.RESULTADOS:Se incluyeron 22 pacientes que ten&#xed;an una mediana de edad de 43 a&#xf1;os (rango 19-64 a&#xf1;os) y una mediana de &#xed;ndice de masa corporal de 31&#x2009;kg / m2 (rango 22-51). La mediana de tiempo entre el intento previo de reparaci&#xf3;n quir&#xfa;rgica y la cirug&#xed;a del gracilis fue de 7 meses (rango 3-17). El n&#xfa;mero de reparaciones previamente intentadas fue: 1-2 (n = 8), 3-4 (n = 9), y &gt;4 (n = 5). El intento de reparaci&#xf3;n quir&#xfa;rgica m&#xe1;s reciente fue el colgajo de avance rectal (n = 7), el colgajo transperineal +/- Martius (n = 4), la episioproctotom&#xed;a (n = 3), la reparaci&#xf3;n transvaginal (n = 2) y otros (n = 6). Todos los pacientes ten&#xed;an derivaci&#xf3;n fecal en el momento de la cirug&#xed;a gracilis. La infecci&#xf3;n del sitio quir&#xfa;rgico posoperatorio a los 30 d&#xed;as en el sitio del injerto / donante fue del 32% (n = 7). Con una mediana de seguimiento de 22 meses (rango 2-62), el cierre de la f&#xed;stula fue del 59% (n = 13). La interposici&#xf3;n de Gracilis fue exitosa en todos los pacientes con enfermedad inflamatoria intestinal.LIMITACIONES:Car&#xe1;cter retrospectivo de los datos.CONCLUSIONES:La interposici&#xf3;n de Gracilis es una t&#xe9;cnica quir&#xfa;rgica eficaz para el cierre reoperatorio de la f&#xed;stula rectovaginal. Se debe asesorar a los pacientes sobre la posibilidad de infecci&#xf3;n del sitio del injerto / donante. Consulte Video Resumen en http://links.lww.com/DCR/B763 . (Traducci&#xf3;n-Dr. Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hull</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapci</LastName><ForeName>Ipek</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Lightner</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3X9MR4N98U</RegistryNumber><NameOfSubstance UI="D003974">Diatrizoate Meglumine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012006" MajorTopicYN="N">Rectovaginal Fistula</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003974" MajorTopicYN="N">Diatrizoate Meglumine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014624" MajorTopicYN="Y">Vaginal Fistula</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34759248</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002249</ArticleId><ArticleId IdType="pii">00003453-202301000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hotouras A, Ribas Y, Zakeri S, Murphy J, Bhan C, Chan CL. Gracilis muscle interposition for rectovaginal and anovaginal fistula repair: a systematic literature review. Colorectal Dis. 2015;17:104&#x2013;110.</Citation></Reference><Reference><Citation>Korsun S, Liebig-Hoerl G, Fuerst A. Gracilis muscle transposition for treatment of recurrent anovaginal, rectovaginal, rectourethral, and pouch-vaginal fistulas in patients with inflammatory bowel disease. Tech Coloproctol. 2019;23:43&#x2013;52.</Citation></Reference><Reference><Citation>Park SO, Hong KY, Park KJ, Chang H, Shin JY, Jeong SY. Treatment of rectovaginal fistula with gracilis muscle flap transposition: long-term follow-up. Int J Colorectal Dis. 2017;32:1029&#x2013;1032.</Citation></Reference><Reference><Citation>Gilshtein H, Strassman V, Wexner SD. Redo gracilis interposition for complex perineal fistulas. Tech Coloproctol. 2020;24:475&#x2013;478.</Citation></Reference><Reference><Citation>Wexner SD, Ruiz DE, Genua J, Nogueras JJ, Weiss EG, Zmora O. Gracilis muscle interposition for the treatment of rectourethral, rectovaginal, and pouch-vaginal fistulas: results in 53 patients. Ann Surg. 2008;248:39&#x2013;43.</Citation></Reference><Reference><Citation>Lef&#xe8;vre JH, Bretagnol F, Maggiori L, Alves A, Ferron M, Panis Y. Operative results and quality of life after gracilis muscle transposition for recurrent rectovaginal fistula. Dis Colon Rectum. 2009;52:1290&#x2013;1295.</Citation></Reference><Reference><Citation>Chen XB, Wang YX, Jiang H, Liao DX, Yu JH, Luo CH. Salvage irrigation-suction in gracilis muscle repair of complex rectovaginal and rectourethral fistulas. World J Gastroenterol. 2013;19:6625&#x2013;6629.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34623348</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients With IBD.</ArticleTitle><Pagination><StartPage>1364</StartPage><EndPage>1373</EndPage><MedlinePgn>1364-1373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002063</ELocationID><Abstract><AbstractText Label="BACKGROUND">Recommendations regarding management of colorectal dysplasia in the setting of IBD continue to evolve.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine the rate of progression from dysplasia to adenocarcinoma, specifically focusing on the differences in unifocal and multifocal low-grade dysplasia and dysplasia found on random biopsy versus targeted biopsies.</AbstractText><AbstractText Label="DESIGN">This is a retrospective review.</AbstractText><AbstractText Label="SETTING">This study was conducted at an IBD referral center.</AbstractText><AbstractText Label="PATIENTS">All adult patients (&#x2265;18 years of age) with a known diagnosis of either ulcerative colitis or Crohn's disease, who underwent a surveillance colonoscopy between January 1, 2010 and January 1, 2019, were selected.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES">The primary outcomes measured were the progression of dysplasia and the risk factors for progression.</AbstractText><AbstractText Label="RESULTS">A total of 23,751 surveillance colonoscopies were performed among 12,289 patients between January 1, 2010 and January 1, 2019. The mean age at colonoscopy was 52.1 years (SD 16.9 years), 307 patients (2.5%) had a history of primary sclerosing cholangitis, and 3887 (3.15%) had a family history of colorectal cancer. There was a total of 668 patients (5.4%) with low-grade dysplasia, 76 patients (0.62%) with high-grade dysplasia, and 68 patients (0.55%) with adenocarcinoma in the series. The 1-, 2-, and 5-year cumulative incidence rate of progressing from low-grade dysplasia to high-grade dysplasia were 1.6%, 4.8%, and 7.8%. The 1- and 2-year cumulative incidence rates of progressing from low-grade dysplasia to adenocarcinoma were 0.7% and 1.6%. There were no significant differences in unifocal and multifocal progression. Primary sclerosing cholangitis, ulcerative colitis, male sex, and advanced age were all found to be significant risk factors for neoplasia on multivariable analysis.</AbstractText><AbstractText Label="LIMITATIONS">A retrospective database was a source of information.</AbstractText><AbstractText Label="CONCLUSION">Progression of low-grade dysplasia to adenocarcinoma, regardless of its being unifocal or multifocal, remains very low in the setting of adequate surveillance and medical management. The presence of multifocal low-grade dysplasia should not change the decision making to pursue ongoing endoscopic surveillance versus proctocolectomy. Patients who had primary sclerosing cholangitis with dysplasia found on random biopsies may be at highest risk for dysplasia progression. See Video Abstract at http://links.lww.com/DCR/A649.</AbstractText><AbstractText Label="EL DESENLACE DE LA DISPLASIA DE BAJO GRADO UNIFOCAL VERSUS MULTIFOCAL DURANTE LA COLONOSCOPIA EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL">ANTECEDENTES:Las recomendaciones para el tratamiento de la displasia colorrectal en el contexto de la enfermedad inflamatoria intestinal siguen evolucionando.OBJETIVO:Determinar la tasa de progresi&#xf3;n de displasia a adenocarcinoma, centr&#xe1;ndose espec&#xed;ficamente en las diferencias en displasia de bajo grado unifocal y multifocal, y displasia encontradas en biopsias aleatorias versus biopsias dirigidas.DISE&#xd1;O:Revisi&#xf3;n retrospectiva.&#xc1;MBITO:Centro de referencia de EII.PACIENTES:Todos los pacientes adultos (&gt; 18 a&#xf1;os) con un diagn&#xf3;stico comprobado de colitis ulcerosa o enfermedad de Crohn que se sometieron a una colonoscopia de vigilancia entre el 1 de enero de 2010 y el 1 de enero de 2019.PRINCIPALES VARIABLES ANALIZADAS:Progresi&#xf3;n de la displasia y factores de riesgo de progresi&#xf3;n.RESULTADOS:Se realizaron un total de 23.751 colonoscopias de vigilancia en 12.289 pacientes entre el 1/1/2010 y el 1/1/2019. La edad media en el momento de la colonoscopia fue de 52,1 a&#xf1;os (DE 16,9 a&#xf1;os), 307 pacientes (2,5%) ten&#xed;an antecedentes de colangitis esclerosante primaria y 3887 (3,15%) ten&#xed;an antecedentes familiares de c&#xe1;ncer colorrectal. Hubo un total de 668 pacientes (5,4%) con displasia de bajo grado, 76 pacientes (0,62%) con displasia de alto grado y 68 pacientes (0,55%) con adenocarcinoma en la serie. La tasa de incidencia acumulada de 1, 2, 5 a&#xf1;os de progresi&#xf3;n de displasia de bajo grado a displasia de alto grado fue del 1,6%, 4,8% y 7,8%. Las tasas de incidencia acumulada de 1 y 2 a&#xf1;os de progresi&#xf3;n de displasia de bajo grado a adenocarcinoma fueron 0,7% y 1,6%, respectivamente. No hubo diferencias significativas en la progresi&#xf3;n unifocal y multifocal. Se encontr&#xf3; que la colangitis esclerosante primaria, la colitis ulcerosa, el sexo masculino y la edad avanzada eran factores de riesgo significativos de neoplasia en el an&#xe1;lisis multivariable.LIMITACIONES:Base de datos retrospectiva.CONCLUSI&#xd3;N:La progresi&#xf3;n de la displasia de bajo grado a adenocarcinoma, independientemente de que sea unifocal o multifocal, sigue siendo muy baja en el contexto de una vigilancia y un tratamiento m&#xe9;dico adecuados. La presencia de displasia multifocal de bajo grado no deber&#xed;a cambiar la toma de decisi&#xf3;n para continuar con vigilancia endosc&#xf3;pica continua o realizar la proctocolectom&#xed;a. Los pacientes con colangitis esclerosante primaria y displasia encontrada en biopsias aleatorias pueden tener una mayor progresi&#xf3;n de la displasia. Consulte Video Resumen en http://links.lww.com/DCR/A649.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lightner</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogler</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaidya</LastName><ForeName>Prashansha S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMichael</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>General Surgery, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Qualitative Health Science, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regueiro</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease Surgical Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Dis Colon Rectum. 2022 Aug 1;65(8):e825. doi: 10.1097/DCR.0000000000002521.</RefSource><PMID Version="1">35661081</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="Y">Colonoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34623348</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002063</ArticleId><ArticleId IdType="pii">00003453-202111000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746&#x2013;774, 774.e1.</Citation></Reference><Reference><Citation>Samadder NJ, Valentine JF, Guthery S, et al. Family history associates with increased risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1807&#x2013;1813 e1.</Citation></Reference><Reference><Citation>Shergill AK, Lightdale JR, Bruining DH, et al. American Society for Gastrointestinal Endoscopy Standards of Practice Committee; The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015;81:1101&#x2013;1121.e1&#x2013;13.</Citation></Reference><Reference><Citation>Annese V, Daperno M, Rutter MD, et al.; European Crohn&#x2019;s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982&#x2013;1018.</Citation></Reference><Reference><Citation>Cairns SR, Scholefield JH, Steele RJ, et al.; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666&#x2013;689.</Citation></Reference><Reference><Citation>Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81:489&#x2013;501.e26.</Citation></Reference><Reference><Citation>Magro F, Gionchetti P, Eliakim R, et al.; European Crohn&#x2019;s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649&#x2013;670.</Citation></Reference><Reference><Citation>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384&#x2013;413.</Citation></Reference><Reference><Citation>Shergill AK, Lightdale JR, Bruining DH, et al.; American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101&#x2013;21.e1, 13.</Citation></Reference><Reference><Citation>Chiu K, Riddell RH, Schaeffer DF. DALM, rest in peace: a pathologist&#x2019;s perspective on dysplasia in inflammatory bowel disease in the post-DALM era. Mod Pathol. 2018;31:1180&#x2013;1190.</Citation></Reference><Reference><Citation>Zisman TL, Bronner MP, Rulyak S, et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis. 2012;18:2240&#x2013;2246.</Citation></Reference><Reference><Citation>Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25:657&#x2013;668.</Citation></Reference><Reference><Citation>Murphy J, Kalkbrenner KA, Pemberton JH, et al. Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. Dis Colon Rectum. 2014;57:993&#x2013;998.</Citation></Reference><Reference><Citation>Cremer A, Demetter P, De Vos M, et al.; Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. Clin Gastroenterol Hepatol. 2020;18:1528&#x2013;1536.e5.</Citation></Reference><Reference><Citation>Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc. 2011;74:1087&#x2013;1093.</Citation></Reference><Reference><Citation>Kisiel JB, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012;18:226&#x2013;235.</Citation></Reference><Reference><Citation>Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis. 2013;7:e684&#x2013;e691.</Citation></Reference><Reference><Citation>Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2:534&#x2013;541.</Citation></Reference><Reference><Citation>Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334&#x2013;339.</Citation></Reference><Reference><Citation>van Schaik FD, Mooiweer E, van der Have M, et al.; Dutch Initiative on Crohn Colitis. Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia. Inflamm Bowel Dis. 2013;19:342&#x2013;349.</Citation></Reference><Reference><Citation>Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295&#x2013;1300.</Citation></Reference><Reference><Citation>Gomoll&#xf3;n F, Dignass A, Annese V, et al.; ECCO. 3rd European Evidence-based consensus on the diagnosis and management of Crohn&#x2019;s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3&#x2013;25.</Citation></Reference><Reference><Citation>Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol. 2019;25:4148&#x2013;4157.</Citation></Reference><Reference><Citation>Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71&#x2013;74.</Citation></Reference><Reference><Citation>Gorfine SR, Bauer JJ, Harris MT, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum. 2000;43:1575&#x2013;1581.</Citation></Reference><Reference><Citation>Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009;69:1299&#x2013;1310.</Citation></Reference><Reference><Citation>Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn&#x2019;s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol. 2008;6:993&#x2013;998.</Citation></Reference><Reference><Citation>Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110:1022&#x2013;1034.</Citation></Reference><Reference><Citation>Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al.; Dutch Initiative on Crohn&#x2019;s and Colitis. Incidence of interval colorectal cancer among inflammatory bowel disease patients undergoing regular colonoscopic surveillance. Clin Gastroenterol Hepatol. 2015;13:1656&#x2013;1661.</Citation></Reference><Reference><Citation>Shah SC, Ten Hove JR, Castaneda D, et al. High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16:1106&#x2013;1113.e3.</Citation></Reference><Reference><Citation>De Jong ME, Van Tilburg SB, Nissen LHC, et al. Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis. 2019;13:1485&#x2013;1491.</Citation></Reference><Reference><Citation>Fumery M, Dulai PS, Gupta S, et al. Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:665&#x2013;674.e5.</Citation></Reference><Reference><Citation>Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634&#x2013;1648.</Citation></Reference><Reference><Citation>Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311&#x2013;1319.</Citation></Reference><Reference><Citation>Farraye FA, Odze RD, Eaden J, et al.; AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738&#x2013;745.</Citation></Reference><Reference><Citation>Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002;45:615&#x2013;620.</Citation></Reference><Reference><Citation>Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology. 1992;103:431&#x2013;438.</Citation></Reference><Reference><Citation>Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639&#x2013;651.e28.</Citation></Reference><Reference><Citation>Askling J, Dickman PW, Karl&#xe9;n P, et al. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet. 2001;357:262&#x2013;266.</Citation></Reference><Reference><Citation>Jess T, Simonsen J, J&#xf8;rgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375&#x2013;381.e1.</Citation></Reference><Reference><Citation>Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:1352&#x2013;1356.</Citation></Reference><Reference><Citation>Venkatesh PG, Jegadeesan R, Gutierrez NG, Sanaka MR, Navaneethan U. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis. 2013;7:968&#x2013;973.</Citation></Reference><Reference><Citation>Lai KK, Horvath B, Xie H, et al. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis. 2015;21:378&#x2013;384.</Citation></Reference><Reference><Citation>Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol. 1989;20:1008&#x2013;1014.</Citation></Reference><Reference><Citation>Kontzoglou K, Moulakakis KG, Alexiou D, et al. The role of liquid-based cytology in the investigation of colorectal lesions: a cytohistopathological correlation and evaluation of diagnostic accuracy. Langenbecks Arch Surg. 2007;392:189&#x2013;195.</Citation></Reference><Reference><Citation>Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn&#x2019;s disease: quality of life after surgical therapy. Int J Colorectal Dis. 2001;16:81&#x2013;87.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>